STOCK TITAN

Kalvista Pharm - KALV STOCK NEWS

Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.

KalVista Pharmaceuticals Inc (KALV) is a clinical-stage biopharmaceutical company advancing novel protease inhibitors for rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.

Our curated collection offers immediate access to KALV's latest press releases, including progress on oral plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema therapies. Track updates across all development phases – from preclinical research to late-stage trials – while staying informed about partnership announcements and financial disclosures.

Key coverage areas include clinical trial results, FDA communications, intellectual property developments, and scientific presentations. The resource is particularly valuable for monitoring KALV's Factor XIIa inhibitor program and comparative effectiveness data against existing therapies.

Bookmark this page for real-time updates on KalVista's innovative pipeline and regulatory progress. For comprehensive tracking of this clinical-stage innovator's journey in protease inhibition therapeutics, we recommend checking back regularly.

Rhea-AI Summary
KalVista Pharmaceuticals, Inc. presents positive data on phase 3 KONFIDENT trial for sebetralstat at AAAAI 2024, showcasing high efficacy with one dose, safety, and flexibility in dosing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces entry into UK Innovative Licensing and Access Pathway (ILAP) for sebetralstat, a plasma kallikrein inhibitor for hereditary angioedema. Late-breaking phase 3 data to be presented at 2024 AAAAI Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
none
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces late-breaking phase 3 data for the KONFIDENT trial at the 2024 AAAAI Annual Meeting. The company presents multiple abstracts on Hereditary Angioedema attacks and treatment patterns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences clinical trial
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces the pricing of its underwritten public offering, expecting gross proceeds of $160.1 million. The offering includes common stock and pre-funded warrants, with an option for additional shares. The pre-funded warrants are immediately exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announces a public offering of common stock and pre-funded warrants to certain investors. The company plans to use the proceeds for the clinical development of its product candidate sebetralstat and other activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces positive results from the phase 3 KONFIDENT clinical trial for sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). The trial showed statistically and clinically significant efficacy, with a favorable safety profile. Sebetralstat achieved symptom relief faster than placebo, with no serious adverse events. The Company plans to submit a new drug application to the U.S. FDA in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) recently granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of KalVista common stock. The options have an exercise price of $15.74 per share and vest over a four-year period. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
none
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces the publication of data on the first report of an oral, potent, and selective FXIIa inhibitor in the peer-reviewed scientific journal, Frontiers in Pharmacology. The article describes the pharmacology of a representative compound from KalVista’s portfolio of oral Factor XII inhibitors, including potent, selective inhibition of both FXII zymogen and FXIIa, blockage of KKS-mediated edema in preclinical HAE models in vivo, and high oral availability in multiple species. This demonstrates KalVista's scientific leadership in medicinal chemistry and KKS biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) completes the targeted number of attacks in the Phase 3 KONFIDENT Clinical Trial for sebetralstat, with data readout expected in early 2024 and NDA filing in H1 2024. The company also achieved Orphan Drug Status in Switzerland and presented real-world patient data at scientific meetings. However, the second fiscal quarter ended with no revenue, increased R&D and G&A expenses, and a net loss of $27.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) granted four newly-hired employees inducement options to purchase 43,000 shares of KalVista common stock on December 1, 2023. The options have an exercise price of $8.82 per share, one-fourth vest on the one-year anniversary, and the remainder vest in equal monthly installments over the next three years, subject to the new employee’s continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Kalvista Pharm

Nasdaq:KALV

KALV Rankings

KALV Stock Data

571.23M
44.06M
1.36%
113.48%
11.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE